7,812 Shares in IDEXX Laboratories, Inc. $IDXX Acquired by Munich Reinsurance Co Stock Corp in Munich

Munich Reinsurance Co Stock Corp in Munich acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 7,812 shares of the company’s stock, valued at approximately $4,991,000.

Other large investors have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC boosted its position in IDEXX Laboratories by 2.5% during the third quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock valued at $397,000 after acquiring an additional 15 shares during the last quarter. STF Management LP grew its holdings in IDEXX Laboratories by 1.3% during the 2nd quarter. STF Management LP now owns 1,240 shares of the company’s stock worth $665,000 after acquiring an additional 16 shares during the period. Clearstead Trust LLC raised its position in shares of IDEXX Laboratories by 1.1% in the 2nd quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock worth $813,000 after acquiring an additional 16 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its position in shares of IDEXX Laboratories by 4.4% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company’s stock worth $243,000 after acquiring an additional 16 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC lifted its stake in shares of IDEXX Laboratories by 3.3% in the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company’s stock valued at $337,000 after purchasing an additional 17 shares during the period. Institutional investors own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In other news, EVP Michael G. Erickson sold 5,371 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total value of $3,369,657.98. Following the completion of the sale, the executive vice president owned 12,693 shares in the company, valued at $7,963,334.34. This represents a 29.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Nimrata Hunt sold 1,758 shares of the stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the completion of the sale, the executive vice president owned 18,141 shares of the company’s stock, valued at approximately $11,511,734.37. This represents a 8.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 45,957 shares of company stock worth $29,862,109. 0.98% of the stock is owned by insiders.

IDEXX Laboratories Stock Down 1.7%

IDXX stock opened at $608.41 on Friday. The firm has a market capitalization of $48.44 billion, a PE ratio of 46.55, a P/E/G ratio of 3.70 and a beta of 1.66. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $769.98. The stock’s 50 day moving average is $666.94 and its 200-day moving average is $668.42.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.93 by ($0.01). The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter last year, the company posted $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Piper Sandler cut their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research report on Monday, February 9th. Weiss Ratings downgraded IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Barclays dropped their price target on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Finally, BTIG Research lowered their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Seven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.